Synaptogenix (NASDAQ:SNPX) Trading Down 0.3% – Here’s Why

Synaptogenix, Inc. (NASDAQ:SNPX) shares were down 0.3% during mid-day trading on Wednesday . The stock traded as low as $2.80 and last traded at $2.90. Approximately 5,379 shares traded hands during trading, a decline of 57% from the average daily volume of 12,482 shares. The stock had previously closed at $2.91.

Synaptogenix Trading Down 0.3 %

The firm has a 50-day moving average of $3.15 and a 200 day moving average of $3.10.

Institutional Investors Weigh In On Synaptogenix

A hedge fund recently bought a new stake in Synaptogenix stock. Geode Capital Management LLC purchased a new position in shares of Synaptogenix, Inc. (NASDAQ:SNPX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,844 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned approximately 0.80% of Synaptogenix at the end of the most recent quarter. Institutional investors and hedge funds own 10.34% of the company’s stock.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.